Roth Tweaks Numbers on Auryxia Ahead of Keryx Pharna's (KERX) Q4 Report; Maintains 'Buy' Rating

Roth Capital is adjusting certain numbers on Keryx Biopharmaceuticals (Nasdaq: KERX) ahead of the company's Q4 report on Thursday.

Analyst Joseph Pantginis is lowering his Q4 sale estimate for Auryxia, thinking initial estimates were too high based on the late 2014 launch. The outlook was cut from $1.8 million down to $0.185 million.

Pantginis continued, The late 2014 launch is also prompting changes to our 2015 and 2016 Auryxia revenue estimates: 1) 2015: $62.3 million to $47.2 million and 2) 2016: $147 million to $128 million.

Pantginis noted that his case on Auryxia is unchanged based on the drug's differentiated properties compared to other drugs for hyperphosphatemia. These properties focus on the potential for reduced i.v. iron and ESA usage.

Roth has Keryx at Buy with a price target of $32.

For an analyst ratings summary and ratings history on Keryx Biopharmaceuticals click here. For more ratings news on Keryx Biopharmaceuticals click here.

Keryx Biopharmaceuticals closed at $11.94 yesterday.

You May Also Be Interested In

• Temenos AG (TEMN:SW) (TMSNY) PT Lowered to CHF65 at Citi
• CONMED (CNMD) PT Lowered to $107 at Needham
• ASM International NV (ASM:NA) PT Raised to EUR720 at Citi